UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549  FORM 10-QSB   [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For quarterly period ended September 30, 2006  [   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Commission File No.  000-30991  SKINOVATION PHARMACEUTICAL INCORPORATED (Exact name of small business issuer as specified in its charter)   Nevada87-0458170(State of incorporation)(I.R.S.  Employer Identification No.)   2157 S. Lincoln Street, Salt Lake City, Utah   84106 (Address of principal executive offices)  (801) 323-2395 (Issuers telephone number)  Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  [X]    No [   ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  [X]    No [   ]  As of October 26, 2006 Skinovation Pharmaceutical Incorporated had a total of 708,000 shares of common stock issued and outstanding.  Transitional small business disclosure format:  Yes [  ]  No [X]  1       TABLE OF CONTENTS  PART I: FINANCIAL INFORMATION  Item 1.  Financial Statements 2  Item 2. Managements Discussion and Analysis or Plan of Operation 7  Item 3. Controls and Procedures 7  PART II: OTHER INFORMATION  Item 6.  Exhibits 8  Signatures 8     PART I:   FINANCIAL INFORMATION   ITEM 1. FINANCIAL STATEMENTS  The financial information set forth below with respect to our statements of operations for the three and nine month periods ended September 30, 2006 and 2005 is unaudited.  This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data.  The results of operations for the nine month period ended September 30, 2006 are not necessarily indicative of results to be expected for any subsequent period.        Skinovation Pharmaceutical Incorporated  (A Development Stage Company)  Financial Statements  September 30, 2006      2        Skinovation Pharmaceutical, Inc.(A Development Stage Company)Balance SheetsASSETSSeptember 30,December 31,20062005(Unaudited)CURRENT ASSETSCash$               3,502$                   771Total Current Assets3,502771TOTAL ASSETS$               3,502$                   771LIABILITIES AND STOCKHOLDER' EQUITYCURRENT LIABILITIESAccounts Payable - Related party$             38,726$              38,726Accounts Payable - Other5,2505,000Accrued Expenses180-Loan Payable9,000-Total Current Liabilities53,15643,726Total Liabilities53,15643,726STOCKHOLDERS' EQUITYCommon Stock, $.001 par value; 50,000,000 sharesauthorized; 708,000 shares issued and outstanding708708Additional Paid in Capital25,14825,148Deficit Accumulated During the Development Stage(75,510)(68,811)Total Stockholders' Equity(49,654)(42,955)TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$               3,502$                     71   The accompanying notes are an integral part of these financial statements.   3        Skinovation Pharmaceutical, Inc.(A Development Stage Company)Statements of Operations(Unaudited)For the three monthsFor the three monthsFor the nine monthsFor the nine monthsFrom Inception onended Sept. 30,ended Sept. 30,ended Sept. 30,ended  Sept. 30,January 15, 19882006200520062005to Sept. 30, 2006REVENUES$                            -$                              -$                             -$                          -$            27,937EXPENSESGeneral & Administrative1,8982226,2711,726140,342TOTAL EXPENSES1,8982226,2711,726140,342NET INCOME (LOSS) FROMCONTINUING OPERATIONS(1,898)(222)(6,271)(1,726)(112,405)OTHER INCOME (EXPENSE)Gain on Disposal of Operations----37,075Interest Expense(180)-(180)-(180)NET INCOME (LOSS) BEFORE TAXES(2,078)(222)(6,451)(1,726)(75,510)TAXES-----NET INCOME (LOSS)$                    (2,078)$                         (222)$                     (6,451)$                 (1,726)$           (75,510)NET LOSS PER SHARE$                             -$                               -$                      (0.01)$                         -$             ( 0.18)WEIGHTED AVERAGE SHARESOUTSTANDING708,000708,000708,000708,000409,786   The accompanying notes are an integral part of these financial statements.         4        Skinovation Pharmaceutical, Inc.(A Development Stage Company)Statement of Cash Flows(Unaudited)From Inception onFor the nine months endedJanuary 15, 1988September 30,Through20062005September 30, 2006Cash Flows from Operating ActivitiesNet Loss$                               (6,451)$                    (1,726)$                  (75,510)Adjustments to reconcile net (loss) to cash provided(used) by operating activities:Shares issued for services--10,433Shares issued for debt payment--1,424Loss on disposal of PP&E5,263Changes in assets and liabilities:Increase in accounts payable & accrued expenses182(168)44,156Net Cash Provided (Used) by Operating Activities(6,269)(1,894)(14,234)Cash Flows from Investing ActivitiesCash paid for PP&E--(5,264)Net Cash Provided (Used) by Investing Activities--(5,264)Cash Flows from Financing ActivitiesCash paid for offering costs--(7,000)Common stock issued for cash--21,000Proceeds from note payable9,000-9,000Net Cash Provided (Used) by Financing Activities--23,000Increase (Decrease) in Cash2,979(1,894)3,502Cash and Cash Equivalents at Beginning of Period7713,037-Cash and Cash Equivalents at End of Period$                                3,502$                     1,143$                      3,502Supplemental Cash Flow Information:Stock issued for debt payment$                                         -$                             -$                      1,424Stock issued for services$                                         -$                             -$                    10,433Cash Paid For:Interest$                                         -$                             -$                              -Income Taxes$                                         -$                             -$                              -  The accompanying notes are an integral part of these financial statements.  5      Skinovation Pharmaceutical Incorporated Notes to the Financial Statements September 30, 2006  GENERAL  Skinovation Pharmaceutical Incorporated (the Company) has elected to omit substantially all footnotes to the financial statements for the nine months ended September 30, 2006 since there have been no material changes (other than indicated in other footnotes) to the information previously reported by the Company in their Annual Report filed on the Form 10-KSB for the twelve months ended December 31, 2005.  UNAUDITED INFORMATION  The information furnished herein was taken from the books and records of the Company without audit.  However, such information reflects all adjustments which are, in the opinion of management, necessary to properly reflect the results of the interim period presented.  The information presented is not necessarily indicative of the results from operations expected for the full fiscal year.  NOTE PAYABLE  During the prior quarter the Company received a loan of $9,000 from an unrelated party.  On August 15, 2006 the terms of the loan were finalized which included an interest rate of 8% per annum and a maturity date of May 25, 2007.  The loan is unsecured. As of September 30, 2006 there was accrued interest on the loan of $180.  6      In this report references to Skinovation, we, us, and our refer to Skinovation Pharmaceutical Incorporated.  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS  The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions.  This report contains these types of statements.  Words such as may, will, expect, believe, anticipate, estimate, project, or continue or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements.  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  ITEM 2.  MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION  During the next twelve months our management intends to actively seek an operating company to acquire or merge with which may provide operating revenue.  Based on current economic and regulatory conditions, management believes that it is possible, if not probable, for a company like ours, without many assets or liabilities, to negotiate a merger or acquisition with a viable private company.  The opportunity arises principally because of the high legal and accounting fees and the length of time associated with the process of going public.  However, should a merger or acquisition prove unsuccessful, it is possible that we may decide not to pursue further acquisition activities and management may abandon its activities and our shares would become worthless.  As of the date of this filing, we have not identified any assets or business opportunities for acquisition.  Potential investors must recognize that because of limited capital available for investigation of business opportunities and managements limited experience in business analysis, we may not discover or adequately evaluate adverse facts about any business opportunity to be acquired.  All risks inherent in new and inexperienced enterprises are inherent in our plan.  It is emphasized that our management may effect transactions having a potentially adverse impact upon our shareholders pursuant to the authority and discretion of our management to complete acquisitions without submitting any proposal to the stockholders for their consideration.  As of September 30, 2006 we had $3,502 cash on hand and total current liabilities of $53,156.  The majority of our operating expenses are related to our reporting obligations under the Exchange Act.  These expenses include legal, accounting and professional services and costs required to prepare and file our reports with the SEC.  We are unable to pay cash for these services and will need to raise additional funds during the next twelve months.  Historically we have relied on related and third parties to pay for costs on our behalf, but in the 2006 second quarter we secured a loan of $9,000 for our cash requirements.  We intend to use any cash to fund our operations for the short term, but will likely continue to rely on related parties to pay for costs on our behalf when we have insufficient cash.  We may repay our debt with cash, if available, or may convert the debt into common stock.  ITEM 3.  CONTROLS AND PROCEDURES  We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC.  This information is accumulated and communicated to our executive officers to allow timely decisions regarding required disclosure.  Our President, who acts in the capacity of principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report.  Based on that evaluation, he concluded that our disclosure controls and procedures were effective.  7        Also, he determined that there were no changes made in our internal controls over financial reporting during the third quarter of 2006 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.  PART II:  OTHER INFORMATION  ITEM 6.  EXHIBITS  Part I Exhibits 31.1 Principal Executive Officer Certification 31.2 Principal Financial Officer Certification 32.1 Section 1350 Certification  Part II Exhibits 3.1 Articles of Incorporation as amended  (Incorporated by reference to exhibit 3.1 of the Form 10-KSB, filed March 29, 2002) 3.2 Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the Form-SB, filed July 11, 2000)     SIGNATURES  In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   SKINOVATION PHARMACEUTICAL INCORPORATED    Date: November 8, 2006 By:/s/ John W. Peters John W. Peters President, Principal Executive Officer, Principal Financial Officer, and Director   8